EMERYVILLE, Calif.–(BUSINESS WIRE)–NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY), a biopharmaceutical company focusing on commercializing Avenova® for the domestic eye care market, announces an exclusive 90-day agreement with NuSight Medical® t…
IVERIC bio’s Zimura®, a Novel Complement C5 Inhibitor, Met its Primary Endpoint and Reached Statistical Significance in a Phase 2b Randomized, Controlled Clinical Trial in Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration
NEW YORK–(BUSINESS WIRE)–IVERIC bio, Inc. announced initial topline data confirming that Zimura® met its prespecified primary endpoint in its Phase 2b clinical trial.
VIDEO: Improvements maintained for 2 years with abicipar for wet AMD
SAN FRANCISCO — Rahul Khurana, MD, of Northern California Retina Vitreous Associates, shared the 2-year results from the CEDAR and SEQUOIA studies, which showed abicipar given every 12 weeks and every 8 weeks was equivalent to ranibizumab every 4 weeks…
VIDEO: Bilateral implantation of Symfony IOL yields high-level patient satisfaction
SAN FRANCISCO — At the American Academy of Ophthalmology meeting, David Teenan, FRCS(Ed), FRCOphth, discusses his poster presentation on bilateral implantation of the Tecnis Symfony IOL (Johnson & Johnson Vision).
VIDEO: Lensar looks to improve cataract surgery results
SAN FRANCISCO — At the Ophthalmology Innovation Summit preceding the American Academy of Ophthalmology meeting, Nick Curtis, CEO of Lensar, discusses three recent advancements for Lensar involving microincision, improvements in cataract surgery results…
Rutgers expert offers advice to avoid risks of Halloween poisoning and allergic reactions
About 41.1 million children in the United States trick-or-treat on Halloween night. Bruce Ruck, managing director of the New Jersey Poison Control Center at Rutgers New Jersey Medical School’s Department of Emergency Medicine, offers the following advi…